Great research by @andreafava on urinary biomarkers for lupus nephritis A#0850 #ACR23 IL-17 and other biomarkers can predict renal fxn loss - better than proteinuria! Article on @RheumNow https://t.co/DeiWFKzNxC

Vasculitis patients associated with increased pregnancy risks Large study of >600 pregnancies in >500 pts Vasculitis pts higher frequency of spontaneous abortion, elective termination, ectopic and molar pregnancy, preterm delivery 12% pre-eclampsia @RheumNow #ACR23 Abs#2425 https://t.co/Nqa77nxSFu

Pregnancy outcome in Vasculitis - Claim database study A#2425 #ACR23 @RheumNow 665 vasculitis pts, LVV 60, MV 160, SVV 217, variable 250 Incr risk of preterm delivery, particularly medically-ind deliv, esp Small vessel vasc (5x risk med-induced) Higer risk pre-eclampsia/eclampsia https://t.co/bWMyY5oqNK

Who knew @FDA_Drug_Info presented #ACR23 posters?! I thought they just issue statements if there was information to be shared! Abst#1822 Bari and Toci use during the pandemic for #COVID19 did not show new safety signals. 1 case HBV reactivation with bari @RheumNow https://t.co/zd7TELsV2j

International collaborative has discussed early referrals for PMR - this is what they’re recommending Better plans to get the right patients into rheumatologists is a big part of helping #MakeRheumForPMR ABST2395 #ACR23 @RheumNow https://t.co/Kea07IGxhG

Antifibrotics in RA-ILD @Juge_P_A Discontinuation in 46% (Mainly GI). Improved FVC trajectory - almost stops decline. Abstr#2479 #ACR23 #ACRbest @RheumNow https://t.co/nZW6TVKefL https://t.co/5BX3PhFhOK

Rashes in Rheumatology at #ACR23 Name the rash? @Rheumnow https://t.co/7CNqOESctW

• https://twitter.com/MeralElRamahiMD/status/1724549330667725059/photo/1

#ACR23 Abstr#2334 Can we achieve #SLE DORIS remission with current therapy? Post-hoc analyses of 3 x RCTs + LTE over 4 years showed anifrolumab therapy was associated with more frequent and sustained remission vs PBO during the 4-year period. Good for long-term outcomes @RheumNow https://t.co/eq02yChTZr

Rashes in Rheumatology at #ACR23 Name the rash? @Rheumnow https://t.co/uFjXEOHczZ

• https://twitter.com/MeralElRamahiMD/status/1724549534309663000/photo/1

Dysautonomia & joint hypermobility/hEDS - we all know that patients often have both, but what groups of symptoms cluster for patients? This French study showed three main groups - need to look at treatment strategies for each group individually #ACR23 ABST1838 @RheumNow https://t.co/UDepsudpXx

TM83 #ACR23 @RheumNow 45yo M b/l sacroiliitis, Rx MTX -> ADA -> MTX + Tofa. No improv Low Ca, & Phos, ALP 239. Nml Vit D, High PTH. DEXA: Osteoporosis FGF23 high PET/CT showed soft tissue density in nasal septum, few cortical breaks Dx: oncogenic osteomalacia 2/2 malignancy https://t.co/EOcYNtovBy

Review of rashes in SLE at #ACR23 by Dr. Katherine Shaw, MD ⭐️Important to recognize rashes of lupus b/c heterogeneity of cutaneous lupus erythematosus subtypes influences response to treatment. @RheumNow https://t.co/u7dwDe9kbt

Real-world tolerability of anti-fibrotics (nintedanib, pirfenidone) in RA-ILD @BrighamWomens: patients do drop out because of AEs, but a decent chunk are okay and do get modest benefit @Juge_P_A @jeffsparks #ACR23 ABST2479 @RheumNow https://t.co/BpM14eizmF

⭐️Important to recognize rashes of lupus b/c heterogeneity of cutaneous lupus erythematosus subtypes influences response to treatment. 🚩Phase II trial of Iberdomide in SLE: ➡️ not associated w/ statistically significant improvement in CLASI-A when including ALL CLE subtypes… https://t.co/LHNqKMALzU https://t.co/K73sXjFTHM

TM84 #ACR23 @RheumNow 49F MS on RTX, severe arthralgias/wt loss, BMI 18. Spontaneous peritonitis, aseptic discitis/osteo, distal radius lucency, hyperammonemia, hypogammaglobulinemia w 1 yr arthritis Dx: Mycoplasma: ureaplasma urealyticam on culture, PCR improved https://t.co/jM0sARLZS7